Halozyme Therapeutics (HALO) reported $264.86 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 35.2%. EPS of $1.11 for the same period compares to $0.79 a year ago.
The reported revenue represents a surprise of +10.82% over the Zacks Consensus Estimate of $238.99 million. With the consensus EPS estimate being $0.95, the EPS surprise was +16.84%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $78.04 million versus the five-analyst average estimate of $69.82 million. The reported number represents a year-over-year change of +33.2%.
- Revenues- Royalties: $168.19 million compared to the $154.85 million average estimate based on five analysts. The reported number represents a change of +39.5% year over year.
- Revenues- Revenues under collaboration agreements: $18.63 million versus the three-analyst average estimate of $23.88 million. The reported number represents a year-over-year change of +11.5%.
- Product sales, Net- Sales of Device Partnered Products: $14.68 million compared to the $12.60 million average estimate based on two analysts. The reported number represents a change of +14.5% year over year.
- Revenues- Product sales, Net- Sales of bulk rHuPH20: $27.03 million compared to the $13.22 million average estimate based on two analysts. The reported number represents a change of +157.1% year over year.
- Product sales, Net- Sales of proprietary products: $36.34 million versus the two-analyst average estimate of $38.71 million. The reported number represents a year-over-year change of +3.1%.
View all Key Company Metrics for Halozyme Therapeutics here>>>
Shares of Halozyme Therapeutics have returned +2.1% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
